Sulzer to start trials on bone growth protein:
This article was originally published in Clinica
Sulzer Medica will begin US clinical trials to examine whether its bone growth protein can repair bone loss associated with periodontal disease. Consisting of a mixture of naturally occurring bone growth factors in a collagen matrix, Ne-Osteo, a bone morphogenic protein (BMP), promotes bone growth. Sulzer Orthopedics Biologics is working with Sulzer Calcitek to develop applications of the Ne-Osteo BMP technology for dental use. Sulzer expects its market in dentistry to grow to $300 million within the next ten years.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.